The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 360:1256-1259 March 19, 2009 Number 12
NextNext

Irbesartan for Heart Failure with Preserved Ejection Fraction

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Massie, B. M.
-PubMed Citation
To the Editor: Although irbesartan failed to improve outcomes in patients with heart failure and a preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) study, Massie et al. (Dec. 4 issue)1 provide us with a better understanding of this disease. In contrast with observational studies showing a mortality of 22 to 29% after 1 year,2,3 in the I-PRESERVE study, the mortality was 5.2% per year. The prognosis was better in part because of the exclusion of patients with serious coexisting conditions. Yet even in this population of patients with "isolated" heart failure and a . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.